These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 34482189)

  • 1. Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors.
    Seethapathy H; Street S; Strohbehn I; Lee M; Zhao SH; Rusibamayila N; Chute DF; Gao X; Michaelson MD; Rahma OE; Choueiri TK; McGregor B; Sonpavde G; Salabao C; Kaymakcalan MD; Wei X; Gupta S; Motwani S; Leaf DE; Reynolds KL; Sise ME
    Eur J Cancer; 2021 Nov; 157():50-58. PubMed ID: 34482189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
    Espi M; Teuma C; Novel-Catin E; Maillet D; Souquet PJ; Dalle S; Koppe L; Fouque D
    Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study.
    Tiu BC; Strohbehn IA; Zhao S; Ouyang T; Hanna P; Wang Q; Gupta S; Leaf DE; Reynolds KL; Sise ME
    Oncologist; 2023 Jun; 28(6):e379-e390. PubMed ID: 36821637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
    Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function.
    Ha SH; Park JH; Jang HR; Huh W; Lim HY; Kim YG; Kim DJ; Oh HY; Lee JE
    BMC Cancer; 2014 Dec; 14():906. PubMed ID: 25466872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.
    Seethapathy H; Zhao S; Chute DF; Zubiri L; Oppong Y; Strohbehn I; Cortazar FB; Leaf DE; Mooradian MJ; Villani AC; Sullivan RJ; Reynolds K; Sise ME
    Clin J Am Soc Nephrol; 2019 Dec; 14(12):1692-1700. PubMed ID: 31672794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute kidney injury in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody vs. immune checkpoint inhibitors: a retrospective real-world study.
    Zhu J; Ding X; Zhang J; Chen B; You X; Chen X; Chen T
    BMC Cancer; 2024 Jun; 24(1):756. PubMed ID: 38914959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
    Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
    Front Immunol; 2020; 11():574271. PubMed ID: 33162990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with immune check point inhibitors and acute kidney injury.
    Valentin A; Møller AKH; Palshof JA; Broberg B; Gravesen E; Svane IM; Hansen D
    Acta Oncol; 2023 Feb; 62(2):121-125. PubMed ID: 36755491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Zhang Y; Chen J; Liu H; Dai J; Zhao J; Zhu S; Zhang X; Liang J; Hu X; Zhao J; Liu Z; Shen P; Sun G; Zeng H
    Cancer Treat Rev; 2024 Sep; 129():102787. PubMed ID: 38905806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study.
    Zhou P; Liu B; Shen N; Fan X; Lu S; Kong Z; Gao Y; Lv Z; Wang R
    Ren Fail; 2024 Dec; 46(1):2326186. PubMed ID: 38466161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
    Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.
    Siddiqui BA; Gheeya JS; Goswamy R; Bathala TK; Surasi DS; Gao J; Shah A; Campbell MT; Msaouel P; Goswami S; Wang J; Zurita AJ; Jonasch E; Corn PG; Aparicio AM; Siefker-Radtke AO; Sharma P; Subudhi SK; Tannir N
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis.
    Paderi A; Gambale E; Botteri C; Giorgione R; Lavacchi D; Brugia M; Mazzoni F; Giommoni E; Bormioli S; Amedei A; Pillozzi S; Matucci Cerinic M; Antonuzzo L
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of CXCL10 for the occurrence of immune-related adverse events in patient with renal cell carcinoma.
    Miura Y; Motoshima T; Anami T; Yano H; Mito R; Pan C; Urakami S; Kinowaki K; Tsukamoto H; Kurahashi R; Murakami Y; Yatsuda J; Fujiwara Y; Kamba T; Komohara Y
    Microbiol Immunol; 2023 Jul; 67(7):345-354. PubMed ID: 36975091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors.
    Liu F; Wang Z; Li X; Zhang Z; Yang Y; Chen J; Chen D; Wu L; Liu X; Han S; Wang F; Wahafu W; Gao Y; Ren S; Xing N; Cai G; Chen X
    Cancer Commun (Lond); 2023 Feb; 43(2):214-224. PubMed ID: 36528491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis.
    Abdelrahim M; Mamlouk O; Lin H; Lin J; Page V; Abdel-Wahab N; Swan J; Selamet U; Yee C; Diab A; Suki W; Abudayyeh A
    Oncoimmunology; 2021 May; 10(1):1927313. PubMed ID: 34104543
    [No Abstract]   [Full Text] [Related]  

  • 19. MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
    Nagasaka H; Kishida T; Kouro T; Igarashi Y; Takebe S; Yamamoto S; Kondo T; Koizumi M; Terao H; Suzuki T; Nakaigawa N; Himuro H; Wei F; Sasada T
    Int J Clin Oncol; 2024 Jun; 29(6):832-839. PubMed ID: 38580797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
    Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
    BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.